$VINC News
Last published 1y ago
- 1y agoVINCVincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SECGlobeNewswireVincerx common stock suspended by Nasdaq inadvertently; will resume trading at the open of business on April 21, 2025 Trading to be permanently suspended by Nasdaq at the open of business on April 23, 2025 SAN MATEO,
- 1y agoVINCVincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down ActivitiesGlobeNewswireSAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC) today announced that it has terminated the previously announced non-binding Letter of Intent (LOI) with Global Digital Holdings
- 1y agoVINCVincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAIGlobeNewswireSAN MATEO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC) today announced that it has entered into a non-binding letter of intent ("LOI") with Global Digital Holdings Inc., conducting
- 1y agoVINCVincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic AlternativesGlobeNewswireSAN MATEO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC) today announced that the previously signed binding Term Sheet between Vincerx, Oqory, Inc., and Vivasor, Inc. for a reverse merger
- 1y agoVINCVincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory's TROP2 Antibody Drug Conjugate, OQY-3258GlobeNewswireSAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting
- 1y agoVINCVincerx Pharma, Inc. Announces Reverse Stock SplitGlobeNewswireSAN MATEO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting
- 1y agoCLBRGETYNEUEVINCKuehn Law Encourages VINC, NEUE, GETY, and CLBR Investors to Contact Law FirmGlobeNewswireNEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 1y agoVINCVincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.GlobeNewswirePALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting
- 1y agoVINCVincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943GlobeNewswirePALO ALTO, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting
- 1y agoVINCVincerx Pharma Reports Third Quarter 2024 Financial ResultsGlobeNewswireContinued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed Phase 1
- 2y agoVINCVincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate UpdatesGlobeNewswireVIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program's potential and validating the VersAptx™ Platform
- 2y agoVINCVincerx Pharma Reports Second Quarter 2024 Financial ResultsGlobeNewswireVincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected at the end of Q3 2024
- 2y agoVINCVincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireVincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC) The
- 2y agoVINCVincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and WarrantsGlobeNewswirePALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock and accompanying
- 2y agoVINCVincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and WarrantsGlobeNewswirePALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to
- 2y agoVINCVincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024GlobeNewswireVIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors VIP943 pharmacokinetic (PK) data shows very
- 2y agoVINCVincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024GlobeNewswirePALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting
- 2y agoVINCVincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateGlobeNewswireVIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a virtual investor event on April 8 at 2:00 PM PT Phase 1 trial
- 2y agoVINCVincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024GlobeNewswirePALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting
- 2y agoVINCVincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in LymphomaGlobeNewswireInvestigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma (DH-DLBCL) patients in
- 2y agoVINCVincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023GlobeNewswirePoster on VIP943, a novel CD123-targeted antibody-drug conjugate (ADC) from our VersAptx™ platform, showcases selectivity, activity, and safety of VIP943 Poster on VIP924, a first-in-class CXCR5-targeted ADC
- 2y agoVINCVincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 1 dose escalation for VIP943 - first antibody-drug conjugate (ADC) from VersAptx™, versatile and adaptable, next-generation bioconjugation platform - moves quickly into 2nd cohort Phase 1 dose escalation
- 3y agoVINCVincerx Pharma To Present Three Posters at ASH 2023 in DecemberGlobeNewswireVIP943 poster supports selectivity and safety of lead CD123 ADC, VIP943, currently in Phase 1 VIP924 poster shows this novel CXCR5-ADC compares favorably with other ADCs in clinical development Enitociclib poster
- 3y agoMGRXPETVPETVWRELI+4New to The Street Airs Televised Corporate Interviews Episodes 521 and 522 as Sponsored Programming on Bloomberg TV and The Fox Business NetworkGlobeNewswireNEW YORK, Oct. 13, 2023 (GLOBE NEWSWIRE) -- New to The Street, an FMW Media business show production, will air its corporate interviews, episodes 521 and 522, as Sponsored Programming on Bloomberg TV and FOX Business
- 3y agoPETVPETVWSWISFVINCNew to The Street Announces TV Corporate Appearances, broadcasting Episode 518 on Newsmax and Episode 519 on FOX Business Network, Airings start on Saturday, October 7, 2023, at 3:30 PM ETGlobeNewswireNEW YORK, Oct. 06, 2023 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces its corporate TV appearances on Newsmax and the FOX Business Network. New to The Street airs Episode
- 3y agoVINCVincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023GlobeNewswirePALO ALTO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting
- 3y agoVINCVincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943GlobeNewswirePALO ALTO, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC)("Vincerx"), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through
- 3y agoVINCVincerx Pharma Announces FDA Clearance of IND for VIP943GlobeNewswirePhase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx' first candidate from next-generation ADC platform and its second IND clearance within 8 months, highlighting Vincerx's development and regulatory
- 3y agoVINCVincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireIND Application filed for potential best-in-class ADC, VIP943; Phase 1 trial expected to begin Q4 2023 Enrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class SMDC Cash balance
- 3y agoVINCVincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireEnrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class αvβ3 small molecule drug conjugate (SMDC) for the treatment of solid tumors IND filing for VIP943, a next-generation antibody-drug
- 3y agoVINCVincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual MeetingGlobeNewswirePALO ALTO, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting
- 3y agoVINCVincerx Pharma Presents Preclinical Data on Novel Small Molecule Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting 2023GlobeNewswirePALO ALTO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting
- 3y agoVINCVincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual MeetingGlobeNewswirePALO ALTO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting
- 3y agoVINCVincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate UpdateGlobeNewswireFirst cohort dosed in Phase 1 first-in-human dose-escalation study of VIP236, an αvβ3 small molecule drug conjugate (SMDC) in advanced solid tumors IND filing for antibody drug conjugate (ADC) VIP943 remains on
- 3y agoVINCVincerx Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023GlobeNewswirePALO ALTO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting
- 3y agoVINCVincerx Pharma to Participate at the SVB Securities Global Biopharma ConferenceGlobeNewswirePALO ALTO, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting
- 3y agoVINCVincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236GlobeNewswireVIP236 is a first-in-class αVβ3 integrin binder SMDC with the potential to address a broad patient population across multiple solid tumor indications Preclinical studies with VIP236 demonstrated promising tumor
- 3y agoVINCVincerx Pharma Provides American Society of Hematology Annual Meeting 2022 Poster Highlights on Enitociclib in Multiple Tumor TypesGlobeNewswireIn a multiple myeloma (MM) preclinical study, antitumor efficacy was observed with enitociclib as a monotherapy and in combination with several anti-MM agents Significant MYC downregulation was observed in patients with
- 3y agoVINCVincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022GlobeNewswireVincerx's proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significant improved safety in non-human primates (NHP) when compared with
- 3y agoDFFNREVBSNCEVINCDiffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci's History of Stockholder Value Destruction and Self-DealingGlobeNewswireDiffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review processDiffusion received bids from more than 15 companies participating in review
- 4y agoVINCVincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewswireReceived Orphan Drug Designation for enitociclib; continue to focus on priority indications IND submission for first-in-class small molecule drug conjugate (SMDC) VIP236 expected by year-end IND filings for antibody
- 4y agoVINCVincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022GlobeNewswirePALO ALTO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting
- 4y agoVINCVincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewswireContinue to execute on priority indications for VIP152; recently issued the INN enitociclib IND submission for first-in-class small molecule drug conjugate (SMDC) VIP236 still expected in 2H2022 IND filings for antibody drug conjugates (ADCs), VIP9
- 4y agoVINCVincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 CongressGlobeNewswirePreclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation Clinical data show improved selectivity, target modulation, early signs of clinical efficacy, an
- 4y agoVINCVincerx Pharma Provides Key Strategic UpdateGlobeNewswirePrioritizing Phase 1b VIP152 studies to focus on double-hit DLBCL and CLL Continuing to advance next-generation modular bioconjugation platform; IND filings for VIP236 in 2H22 and for VIP943 in 2H23 remain on track Streamlining and realigni
- 4y agoVINCVincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewswireCompany to present poster on VIP152 at upcoming European Hematology Association Annual Meeting Presented preliminary findings on VIP152 in gynecologic malignancies in poster at AACR Annual Meeting Continues to execute on Phase 1b VIP152 cli
- 4y agoVINCVincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Gynecologic Malignancies at the American Association for Cancer Research (AACR) Annual Meeting 2022GlobeNewswireVIP152 demonstrates antitumor responses in preclinical models of gynecologic malignancies Preliminary monotherapy clinical results presented for VIP152-treated patients with gynecologic cancers PALO ALTO, Calif., April 08, 2022
- 4y agoVINCVincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate UpdateGlobeNewswireDosed first patient in VIP152 and pembrolizumab combination arm of study VNC-152-101 Preliminary findings in gynecologic malignancies will be presented as a poster at upcoming AACR Annual Meeting in April 2022 Anticipate initiating Phase 2 studies
- 4y agoVINCVincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022GlobeNewswirePALO ALTO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster
- 4y agoVINCVincerx Pharma to Participate in the SVB Leerink 11th Annual Global Healthcare ConferenceGlobeNewswirePALO ALTO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vinc